The Hemophilia Inhibitor Prevention Trial
Public ClinicalTrials.gov record NCT04303559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Study identification
- NCT ID
- NCT04303559
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Margaret Ragni
- Other
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Interventions
- Eloctate Injectable Product Drug
- Emicizumab Injection [Hemlibra] Drug
Drug
Eligibility (public fields only)
- Age range
- 4 Months to 4 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2021
- Primary completion
- Apr 5, 2022
- Completion
- Jun 15, 2022
- Last update posted
- Apr 10, 2023
2021 – 2022
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas Medical Sciences Childrens Hospital | Little Rock | Arkansas | 72202 | — |
| Hemophilia Center of Western PA | Pittsburgh | Pennsylvania | 15213 | — |
| University of Pittsburgh and Hemophilia Center Western PA | Pittsburgh | Pennsylvania | 15213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04303559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 10, 2023 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04303559 live on ClinicalTrials.gov.